Theravance Seeks A Way Back From Second Ampreloxetine Disappointment
With New MSA Focus
The US firm’s ampreloxetine flunked a second Phase III orthostatic hypotension study but positive data in a prespecified subset have left a narrow path for a potential collaboration and approval, its CEO tells Scrip.
